X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9) 9
female (8) 8
male (8) 8
aged (7) 7
carcinoma, non-small-cell lung - drug therapy (7) 7
middle aged (7) 7
adult (6) 6
carcinoma, non-small-cell lung - pathology (6) 6
index medicus (6) 6
lung neoplasms - drug therapy (6) 6
lung neoplasms - pathology (6) 6
neoplasm staging (6) 6
cancer (5) 5
chemotherapy (5) 5
oncology (5) 5
deoxycytidine - analogs & derivatives (4) 4
docetaxel (4) 4
life sciences (4) 4
respiratory system (4) 4
1st-line chemotherapy (3) 3
antineoplastic agents - therapeutic use (3) 3
carcinoma, squamous cell - pathology (3) 3
cisplatin - administration & dosage (3) 3
deoxycytidine - administration & dosage (3) 3
erlotinib hydrochloride (3) 3
induction chemotherapy (3) 3
lung cancer (3) 3
lung cancer, non-small cell (3) 3
lung neoplasms (3) 3
lung neoplasms - mortality (3) 3
non-small-cell lung cancer (3) 3
plus (3) 3
prospective studies (3) 3
quinazolines - administration & dosage (3) 3
research (3) 3
research article (3) 3
supportive care (3) 3
survival rate (3) 3
trial (3) 3
[sdv.spee]life sciences [q-bio]/santé publique et épidémiologie (2) 2
adenocarcinoma - mortality (2) 2
adenocarcinoma - pathology (2) 2
aged, 80 and over (2) 2
antineoplastic agents (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - economics (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
cancer research (2) 2
cancer therapies (2) 2
carcinoma, non-small-cell lung (2) 2
carcinoma, non-small-cell lung - economics (2) 2
carcinoma, non-small-cell lung - mortality (2) 2
carcinoma, non-small-cell lung - radiotherapy (2) 2
carcinoma, squamous cell - drug therapy (2) 2
carcinoma, squamous cell - mortality (2) 2
cell lung-cancer (2) 2
cisplatin - adverse effects (2) 2
complications and side effects (2) 2
cost-utility (2) 2
disease-free survival (2) 2
drug therapy (2) 2
erlotinib (2) 2
follow-up studies (2) 2
france (2) 2
gemcitabine (2) 2
genetics (2) 2
guanine - analogs & derivatives (2) 2
lung neoplasms - economics (2) 2
mesh: antineoplastic agents (2) 2
mesh: carcinoma, non-small-cell lung (2) 2
mesh: female (2) 2
mesh: humans (2) 2
mesh: lung neoplasms (2) 2
mesh: male (2) 2
mesh: neoplasm staging (2) 2
mesh: taxoids (2) 2
pemetrexed (2) 2
prognosis (2) 2
quality of life (2) 2
quality-of-life (2) 2
radiotherapy (2) 2
salvage therapy (2) 2
santé publique et épidémiologie (2) 2
survival (2) 2
survival analysis (2) 2
taxoids (2) 2
taxoids - therapeutic use (2) 2
time factors (2) 2
treatment outcome (2) 2
[ sdv.can ] life sciences [q-bio]/cancer (1) 1
[ sdv.sp.med ] life sciences [q-bio]/pharmaceutical sciences/medication (1) 1
[ sdv.spee ] life sciences [q-bio]/santé publique et épidémiologie (1) 1
[sdv.can]life sciences [q-bio]/cancer (1) 1
[sdv.sp.med]life sciences [q-bio]/pharmaceutical sciences/medication (1) 1
activities of daily living (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma in situ - mortality (1) 1
adenocarcinoma in situ - pathology (1) 1
adjuvant chemotherapy (1) 1
age factors (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
BMC Cancer, ISSN 1471-2407, 03/2014, Volume 14, Issue 1, p. 231
Journal Article
BMC Cancer, ISSN 1471-2407, 12/2014, Volume 14, Issue 1, p. 953
Journal Article
Interactive CardioVascular and Thoracic Surgery, ISSN 1569-9293, 06/2015, Volume 20, Issue 6, pp. 783 - 790
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2011, Volume 6, Issue 1, pp. 161 - 168
Journal Article
Lung Cancer, ISSN 0169-5002, 2007, Volume 57, Issue 1, pp. 72 - 78
Summary Context The objective of this study was to evaluate the feasibility and activity of weekly docetaxel monotherapy in frail elderly patients with... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Chemotherapy | Comorbidity | Elderly | Lung cancer | Phase II trial | VINORELBINE | elderly | RANDOMIZED-TRIAL | FUNCTIONAL STATUS | chemotherapy | lung cancer | IMPACT | comorbidity | ONCOLOGY | RESPIRATORY SYSTEM | QUALITY-OF-LIFE | phase II trial | SCHEDULES | Taxoids - toxicity | Lung Neoplasms - drug therapy | Follow-Up Studies | Nausea - chemically induced | Humans | Lung Neoplasms - pathology | Male | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Diarrhea - chemically induced | Antineoplastic Agents - toxicity | Feasibility Studies | Time Factors | Aged, 80 and over | Female | Carcinoma, Non-Small-Cell Lung - pathology | Drug Administration Schedule | Anemia - chemically induced | Disease-Free Survival | Taxoids - administration & dosage | Vomiting - chemically induced | Survival Analysis | Quality of Life | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Health Status | Neoplasm Staging | Antimitotic agents | Cancer patients | Oncology, Experimental | Clinical trials | Respiratory tract diseases | Product development | Research | Antineoplastic agents | Lung cancer, Non-small cell | Cancer | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Life Sciences | Taxoids | Vomiting | Anemia | Antineoplastic Agents | Diarrhea | Fatigue | Nausea | Santé publique et épidémiologie
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 07/2013, Volume 8, Issue 7, pp. 906 - 914
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.